vatalanib
Small molecule targets CSF1R, KIT via inhibition
Trials 35
Evidence & citations 16 cited values
Every value below carries the sentence it was read from. 41 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | vatalanib | “Phase II trial of PTK787/ZK 222584 (vatalanib) administered orally once-daily or in two divided daily doses as second-line monotherapy in relapsed or progressing patients with...” PMID 21617019 ↗ May 201116“Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard...” PMID 20821342 ↗ Sep 2010 “PTK787 (vatalanib)” NCT00303732 ↗ |
| Known as | BAY-86-5127 | ChEMBL registry synonym — accepted as the source's own label CHEMBL101253 ↗ |
| Known as | CGP-79787 | ChEMBL registry synonym — accepted as the source's own label CHEMBL101253 ↗ |
| Known as | K-222584 | ChEMBL registry synonym — accepted as the source's own label CHEMBL101253 ↗ |
| Known as | NVP-PTK787 | ChEMBL registry synonym — accepted as the source's own label CHEMBL101253 ↗ |
| Known as | PTK/ZK | “PTK787/ZK222584 (PTK/ZK, vatalanib), a multiple VEGF receptor inhibitor, blocks the intracellular tyrosine kinase activity of all known VEGF receptors and is therefore suitable...” PMID 19945857 ↗ Nov 20091“PTK787/ZK 222584 (PTK-ZK) taken orally with a daily flat dose of 1250 mg on days 1 to 28 (= 1 cycle)” NCT00615160 ↗ |
| Known as | PTK/ZK222584 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00611689 ↗ |
| Known as | PTK787 | “Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard...” PMID 20821342 ↗ Sep 201010“Imatinib and PTK787/ZK222584 in Refractory and/or Advanced Solid Tumors” NCT00611689 ↗ |
| Known as | PTK787/ZK222584 | “PTK787/ZK222584 (PTK/ZK, vatalanib), a multiple VEGF receptor inhibitor, blocks the intracellular tyrosine kinase activity of all known VEGF receptors and is therefore suitable...” PMID 19945857 ↗ Nov 200915“The purpose of this study is to examine if PTK787/ZK222584 (vatalanib) will stabilize or decrease rising biochemical markers along with progressive disease or syndrome symptoms...” NCT00590343 ↗ “Phase II trial of PTK787/ZK 222584 (vatalanib) administered orally once-daily or in two divided daily doses as second-line monotherapy in relapsed or progressing patients with...” PMID 21617019 ↗ May 2011 “A phase 2 study of vatalanib (PTK787/ZK222584) an oral tyrosine kinase inhibitor of VEGFR 1, 2 and 3 was undertaken in patients with metastatic melanoma.” PMID 20800475 ↗ Aug 2010 “PTK787/ZK 222584 (vatalanib)” NCT00171587 ↗ |
| Known as | Vatalanib succinate | ChEMBL registry synonym — accepted as the source's own label CHEMBL101253 ↗ |
| Known as | ZK222584 | “Imatinib and PTK787/ZK222584 in Refractory and/or Advanced Solid Tumors” NCT00611689 ↗1“PTK787/ZK 222584, a drug that blocks new blood vessel growth” NCT00134355 ↗ |
| Action | Inhibit | “PTK787/ZK 222584 may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth.” NCT00053885 ↗2“Macrophage colony stimulating factor receptor inhibitor” CHEMBL101253 ↗ “Stem cell growth factor receptor inhibitor” CHEMBL101253 ↗ |
| Modality | Small molecule | “small-molecule vascular endothelial growth factor receptor inhibitor” PMID 21464406 ↗ Apr 2011 |
| Route | Oral | “A Phase II Open-Label Study of Oral, Continuous, Once Daily PTK787/ZK 222584” NCT00052013 ↗ |
| Target | CSF1R | “Macrophage colony stimulating factor receptor inhibitor” CHEMBL101253 ↗ |
| Target | KIT | “Stem cell growth factor receptor inhibitor” CHEMBL101253 ↗ |